Lifitegrast is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Lifitegrast was developed by Novartis Pharmaceuticals.
The API has now reached off-patent status, after being launched in 2016.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Lifitegrast was exported from India in 2023 , with an average price over the period of $15258 /kg.
The key suppliers were MSN Laboratories, with a focus on markets in MEA.

For enquiries regarding more detailed trade data of Lifitegrast and many others, contact info@pharmacheminvestor.com